|Bid||0.00 x 900|
|Ask||0.00 x 3000|
|Day's Range||88.70 - 89.21|
|52 Week Range||72.30 - 94.19|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||15.59|
|Forward Dividend & Yield||2.94 (3.31%)|
|1y Target Est||100.00|
Adamis Pharmaceuticals Corp. shares surged in the extended session Wednesday after the biotech company said its partner Sandoz Inc. launched an alternative to epinephrine auto-injectors like Mylan NV's EpiPen. Adamis shares rallied 14% after hours, after closing up 4.8% at $2.63 in regular trading Wednesday. Adamis said that Sandoz, which is part of Novartis AG , launched Symjepi, a single-dose treatment for allergic reactions including anaphylaxis. "With recent news of epinephrine product shortages in the U.S., we worked together with Sandoz in getting this potentially life-saving quality product into the market as quickly as possible," said Dennis Carlo, chief executive at Adamis, in a statement.
Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.
Tilray (NASDAQ:TLRY) announced on Dec. 18 that it was expanding its partnership with Sandoz, part of drug giant Novartis (NYSE:NVS). Under the deal, which caused Tilray stock to rally, Sandoz's global-sales team will market Tilray's medical-cannabis products. Four days later, Tilray announced that it was partnering with Anheuser-Busch (NYSE:BUD) to research cannabis-infused drinks. That news also created a buzz around Tilray stock. Inevitably, as cannabis companies in Canada and elsewhere stake their claims to different parts of the cannabis industry, comparisons will be made to the Gold Rush of the 1800s. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks at Risk of the Global Smartphone Slowdown And as in the days of the Gold Rush, there will be winners, losers, and posers. ### Is Tilray Stock a Winner, a Loser or a Poser? Unlike Cronos Group (NASDAQ:CRON) and Canopy Growth (NYSE:CGC), Tilray isn't interested in getting investments from large companies, as TLRY prefers to remain completely independent. "We obviously want to partner with other global pioneers and other leaders in their respective sectors," Tilray CEO Brendan Kennedy said about the partnerships. "We think it's too early to give up control of our own destiny." Those appear to be the words of someone who's going to remain CEO of an independent TLRY for a long time. Of course, it could also be PR speak for "We haven't gotten the right offer just yet." Whatever the true motivations of Tilray's CEO and board, its partnerships could prove to be very beneficial for Tilray stock over the long-term. However, it's not uncommon for big, multinational companies to blow hot and cold. Either of Tilray's partners could lose interest, pay a breakup fee, and end the partnership. Getting a big investment like the one that Canopy's gotten from Constellation Brands (NYSE:STZ) is far more permanent; it's also a sign that Canopy is serious about being a smaller piece of a much bigger pie. Tilray might believe that it's in control of its destiny at the moment, but it can lose that control very quickly. TLRY had operating losses of $34 million on $27.6 million in sales through the first nine months of its fiscal year. To win the cannabis wars, companies need deep pockets and experience. Canopy has both. Tilray doesn't. ### It's Not a Poser I don't think there's any way you can consider Tilray a poser. Anheuser-Busch and Sandoz wouldn't have signed on to these deals if they had a sniff of doubt about Tilray's bona fides. However, as InvestorPlace's Luke Lango pointed out in late December, the BUD partnership is not a huge catalyst that can move TLRY stock back into triple digits. "A $50 million commitment from AB InBev (a $130 billion company) is a drop in the ocean," Lango stated in an article published on Dec. 28. "The language in the press release also doesn't imply that AB InBev and Tilray will be 'lifetime partners,' and that stands in stark contrast to the bullish language in the Cronos and Canopy deal press releases." Tilray's CEO, Brendan Kennedy, believes that there will be three cannabis companies with $100 billion valuations, and he hopes that Tilray stock will be one of them. He also thinks that Tilray will be one of three companies in the sector with annual sales of $50 billion. That seems brash for a company that's projected to generate just $140 million of sales in 2019. Kennedy might want to tone down the rhetoric because it likely will come back to bite him in the rear end. ### The Bottom Line on Tilray Stock While Tilray has been in the news a lot in recent weeks, the company's dealmaking has done little to move TLRY stock. Tilray stock can only rise meaningfully if the company delivers better results in the fourth quarter or if it changes its philosophy and sells a chunk of its business to a company like Diageo (NYSE:DEO). Investors want results now. That's a terrible situation for companies like Tilray that have long-range plans. As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Will Tilrayas Dealmaking Lift Tilray Stock in 2019? appeared first on InvestorPlace.
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Britain's drug price watchdog on Thursday rejected Novartis's migraine drug Aimovig for now, concluding in a draft decision that the medicine was not a cost-effective use of National Health Service resources. Novartis, with exclusive rights to the drug in Europe while cooperating with Amgen in the United States, said it was "disappointed" in the National Institute for Health and Care Excellence's (NICE) conclusion. It marks the second time within months the U.K. agency has rejected reimbursement for a key medicine from the Swiss drugmaker.
Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.
Novartis is one of the companies leading in innovation in medicines and cutting-edge drugs. Narasimhan said the company makes consistent investments into research and development every year. Novartis also has drugs on the horizon to treat arthritis and even heart failure.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...
Jim Cramer explains why it might be worth picking up shares of Micron now despite a possible negative quarter on the horizon.
Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.
Crispr Therapeutics popped Friday after the FDA said it would expedite review of its Vertex Pharmaceuticals-partnered gene-editing sickle cell disease treatment.
Google life sciences spinout Verily Life Sciences LLC lined up a $1 billion investment — the largest biotech investment of the past 12 months — as it looks at strategic partnerships, new businesses globally and potential acquisitions.
Bristol-Myers' (BMY) obtains FDA approval for the label expansion of leukemia drug Sprycel to include pediatric population.
Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.